Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M

INTERPACE BIOSCIENCES, INC.

2025-Q2 EPS reported $0.04 revenue$20,747,000

Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.
Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.
Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.
One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.
Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.